Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala

Indian Journal of Human Genetics

Volumn 20, Issue 2, 2014, Pages 175-184

  Mahadevan, Lakshmi ^a   Yesudas, Ancy ^a   Sajesh, P K ^a   Revu, S ^a   Kumar, Prasanna ^a   Santhosh, Devi ^a   Santhosh, Sam ^a   Sashikumar, J M ^b   Gopalakrishnan, V K ^b   Boben, Joji ^c   Rajesh, Changanamkandath ^a  

^a SCIGENOM LABS PVT LTD   (India)

^b KARPAGAM UNIVERSITY   (India)

^c St Thomas Hospital   (India)

Author keywords

Cardiovascular disease; Drug response; Drug toxicity; Genetic testing

Indexed keywords

CARDIOVASCULAR AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; WARFARIN;

AGED; ALLELE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYBPC3 GENE; MYOPATHY; PREVALENCE; VKORC1 GENE;

EID: 84908501987     PISSN: 09716866     EISSN: 1998362X     Source Type: Journal    
DOI: 10.4103/0971-6866.142896     Document Type: Article

References (36)

1. World Health Organization. Preventing chronic diseases: A vital investment. 2005. Available from: http://www.whqlibdoc.who.int/publications/2005/9241593598-eng.pdf. [Last accessed on 2013 Jan 17].
2. Raghuvanshi VP, Agarwal R. Diet, lifestyle and cardiovascular disease. Int J Pharm Sci Health Care 2012;2:22-32.
3. Soman CR, Kutty VR, Safraj S, Vijayakumar K, Rajamohanan K, Ajayan K, et al. All-cause mortality and cardiovascular mortality in Kerala state of India: Results from a 5-year follow-up of 161, 942 rural community dwelling adults. Asia Pac J Public Health 2011;23:896-903.
4. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008;94:16-26.
5. Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 2007;297:286-94.
6. McPherson R. From genome-wide association studies to functional genomics: New insights into cardiovascular disease. Can J Cardiol 2013;29:23-9.
7. Dhandapany PS, Sadayappan S, Xue Y, Powell GT, Rani DS, Nallari P, et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet 2009;41:187-91.
8. Simonson TS, Zhang Y, Huff CD, Xing J, Watkins WS, Witherspoon DJ, et al. Limited distribution of a cardiomyopathy-associated variant in India. Ann Hum Genet 2010;74:184-8.
9. Fedacko J, Singh RB, Chaithiraphan S, Vargová V, Tomlinson B, De Meester F, et al. Clinical manifestations of adverse effects of statins, oxidative stress and possible role of antioxidants in prevention. Open Nutraceuticals J 2010;3:154-65.
10. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy - A genomewide study. N Engl J Med 2008;359:789-99.
11. Dumas TE, Hawke RL, Lee CR. Warfarin dosing and the promise of pharmacogenomics. Curr Clin Pharmacol 2007;2:11-21.
12. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55.
13. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526.
14. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, et al. Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010;115:3827-34.
15. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
16. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005;14:1745-51.
17. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
18. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51.
19. Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005;366:1744-9.
20. Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, et al. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet 2011;12:136.
21. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: Ago-DARTS study. Clin Pharmacol Ther 2011;89:210-6.
22. Lee CR. CYP2C9 genotype as a predictor of drug disposition in humans. Methods Find Exp Clin Pharmacol 2004;26:463-72.
23. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001;51:277-80.
24. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997;7:405-9.
25. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK, et al. CYP2C9 and CYP2C19 genetic polymorphisms: Frequencies in the South Indian population. Fundam Clin Pharmacol 2005;19:101-5.
26. Yang ZF, Cui HW, Hasi T, Jia SQ, Gong ML, Su XL. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res 2010;9:1844-51.
27. Rathore SS, Agarwal SK, Pande S, Mittal T, Mittal B. The impact of VKORC1-1639 G > A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: A pilot study. Indian J Hum Genet 2011;17 Suppl 1:S54-7.
28. Luo HR, Poland RE, Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: A cross-ethnic comparative study. Clin Pharmacol Ther 2006;80:33-40.
29. Indian Genome Variation Consortium. Genetic landscape of the people of India: A canvas for disease gene exploration. J Genet 2008;87:3-20.
30. Reich D, Thangaraj K, Patterson N, Price AL, Singh L. Reconstructing Indian population history. Nature 2009;461:489-94.
31. Hitchen L. Adverse drug reactions result in 250, 000 UK admissions a year. BMJ 2006;332:1109.
32. Kamali F, Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clin Pharmacol 2006;61:746-51.
33. Peters BJ, Klungel OH, de Boer A, Maitland-van der Zee AH. Genetic determinants of response to statins. Expert Rev Cardiovasc Ther 2009;7:977-83.
34. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010;95:2015-22.
35. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81.
36. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010;11:493-6.